Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMAB009 + FOLFIRI in mCRC
NCT03206151Phase 3Completed
- Sponsor
- Taizhou Mabtech Pharmaceutical
- Start
- Dec 2017
- Primary completion
- May 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of cetuximab in metastatic colorectal cancer (mCRC), sponsored by Taizhou Mabtech Pharmaceutical. Started Dec 2017; status: completed.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03206151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03206151.